Last reviewed · How we verify
NCT04972812
The Effects of Posture on Cerebral Blood Flow Velocity During the Acute Phase of Stroke
trial in Ischemic Stroke in 32 participants. Completed in 31 August 2022.
31 May 2022
Quick facts
| Lead sponsor | Sheffield Hallam University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 32 |
| Start date | 1 July 2021 |
| Primary completion | 31 May 2022 |
| Estimated completion | 31 August 2022 |
| Sites | 1 location across United Kingdom |
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
- Haemorrhagic Stroke — all drugs for Haemorrhagic Stroke →
- Cerebrovascular Accident — all drugs for Cerebrovascular Accident →
- Acute Stroke — all drugs for Acute Stroke →
Sponsor
Sheffield Hallam University
Who can join
18 and older, any sex, with Ischemic Stroke or Haemorrhagic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
After stroke, blood vessels in the brain can become damaged, and the brain's ability to control blood flow can be impaired. The brain therefore may be less able to maintain a healthy level of blood flow during challenges such as changes in posture. Studies have shown that sitting upright early after stroke can cause brain blood flow to reduce. However, no studies have investigated how standing up affects blood flow to the brain. In this study, transcranial Doppler ultrasound will be used to assess how cerebral blood flow velocity changes when acute stroke patients stand up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04972812
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Other Sheffield Hallam University trials
Trials by the same sponsor.
- NCT07373483 — Observing 3-5 Year Old Children's Use of Interactive Electronic Devices (IED) in the Family Home to Understand the Conte · recruiting
- NCT07585474 — Gut Microbiome Response to Long-Haul Travel in Elite Football Players · NA · enrolling by invitation
- NCT06810570 — The Effect of Mobile Devices on the Development and Health of Young Children · recruiting
- NCT06094517 — What Are Persistent Lower Back Pain Patients' Views of Sleep Health Within an Outpatient Musculoskeletal Physiotherapy S · unknown
- NCT06101875 — Health Coaching for Patients Waiting for Hip or Knee Replacements · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04972812 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sheffield Hallam University
- Last refreshed: 9 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04972812.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing